e-Drug3D

1876

LETERMOVIR

INN
LETERMOVIR

cas 917389-32-3

CLASS

ANTIINFECTIVES
DNA TERMINASE COMPLEX (PUL51, PUL56, AND PUL89) INHIBITOR
PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION

ROUTE (list)

ORAL INTRAVENOUS

ATC code

J05AX18

PK parameters

F 94 PERCENT
Tmax 1.25 HOUR
VD 45.5 LITER
PPB 99 PERCENT
t1/2 12 HOUR

Solubility

VERY SLIGHTLY SOLUBLE IN WATER

Target

TARGET DNA TERMINASE COMPLEX

DrugCentral

DNA terminase complex UNIPROT F5HC79 TRM1

Download SDF file

4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-, (4S)-

Formula:
C29H28F4N4O4

Calculated chemical properties:

MW 571.55
NB_atoms 41
XLogP 4.37
PSA 73.261
NB_HD 0
NB_HA 8
fsp3 0.31
Lipinski(0=no;1=yes) 0

FDA
NDA 209939 (pdf not found) INN (LETERMOVIR) PREVYMIS (MERCK SHARP DOHME) APPROVAL= AP YEAR= 2017
NDA 209940 (pdf not found) INN (LETERMOVIR) PREVYMIS (MERCK SHARP DOHME) APPROVAL= AP YEAR= 2017
NDA 216799 (pdf not found) INN (LETERMOVIR) LETERMOVIR (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2024
NDA 219104 (pdf not found) INN (LETERMOVIR) PREVYMIS (MSD) APPROVAL= AP YEAR= 2024